04:36 AM EDT, 04/11/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said late Thursday that argenx (ARGX) received the US Food and Drug Administration's approval for Vyvgart hytrulo prefilled syringe for self-injection to treat adult patients with generalized myasthenia gravis.

The company said the treatment is for anti-acetylcholine receptor antibody-positive patients and adult patients with chronic inflammatory demyelinating polyneuropathy.

The single-dose prefilled subcutaneous injection was developed in Argenx's exclusive partnership with Halozyme.

"We are delighted that Argenx continues to expand use of Halozyme's proven ENHANZE technology to support patient independence and convenience," said Helen Torley, chief executive officer of Halozyme.